Metabolic Health
GLP-1 and Inflammation
Semaglutide measurably lowers a key inflammation marker in trial data, independent of how much weight is lost. Here is w...
Fatty liver is the most common liver condition in the world, it usually causes no symptoms until it is advanced, and it is particularly common in South Asian populations at body weights that look unremarkable.
It also now has an approved drug treatment, which it did not have a few years ago.
What fatty liver is
MASLD, metabolic dysfunction-associated steatotic liver disease, means excess fat accumulating in liver cells. It was previously called non-alcoholic fatty liver disease.
MASH, metabolic dysfunction-associated steatohepatitis, is the more serious stage where that fat causes inflammation and liver cell damage. Previously called NASH.
The progression runs: fat accumulation, then inflammation, then fibrosis where scar tissue forms, then cirrhosis where the liver becomes permanently scarred and function fails.
Fibrosis is graded from stage 1 to stage 4. Early stages can improve. Cirrhosis largely cannot.
Why it matters so much here
South Asian populations develop fatty liver at lower body weights than Western populations.
The reason is body composition. At any given BMI, South Asians tend to carry proportionally more visceral fat, the metabolically active fat around the organs, and less subcutaneous fat. Visceral fat is what drives liver fat accumulation and insulin resistance.
The practical consequence is that a Pakistani adult with a BMI of 26, which looks mild by standard thresholds, may already have significant fatty liver.
It is also strongly linked to type 2 diabetes, which is highly prevalent here, and each worsens the other.
The problem with detection
Fatty liver is usually silent. There are no reliable early symptoms.
It is most often found incidentally, on an abdominal ultrasound performed for something else, or through raised liver enzymes on a routine blood test.
Even then, enzymes can be normal in the presence of significant disease.
That means many people carry it without knowing, and it can progress to fibrosis before anything prompts investigation.
What the ESSENCE trial found
ESSENCE was a two-part, phase 3, randomised multicentre trial of once-weekly semaglutide 2.4 mg in participants with biopsy-proven MASH and fibrosis stage 2 or 3, meaning moderate or advanced scarring.
It had two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and improvement in fibrosis without worsening steatohepatitis.
The results, published in the New England Journal of Medicine in 2025, found semaglutide improved liver histologic results. Gastrointestinal adverse events were more common in the semaglutide group, consistent with the drug class.
Histology means the liver tissue itself, assessed by biopsy. That is a considerably stronger endpoint than a blood test or scan improving.
Following ESSENCE, the FDA approved semaglutide for MASH with fibrosis in August 2025.
That is significant. It means semaglutide now carries a liver indication rather than being used off-label for it.
Why it works
Most of the benefit runs through weight reduction and insulin sensitivity.
Less visceral fat reduces the fatty acid supply reaching the liver.
Improved insulin sensitivity reduces the liver's own fat production, since high insulin drives fat synthesis there.
Reduced inflammation addresses the mechanism that converts simple fat accumulation into damage.
Some analyses suggest effects beyond what weight loss alone would predict, though weight reduction accounts for a large share.
What else works
Worth stating, because a drug is not the only route and is not available to most people here.
Weight loss is the established treatment. Roughly 5 percent reduction improves liver fat, 7 to 10 percent can resolve steatohepatitis, and around 10 percent or more is associated with fibrosis improvement. The threshold rises with the severity of what you are trying to reverse.
Reducing fructose and sugary drinks matters specifically, since fructose is metabolised in the liver and directly promotes fat production there.
Reducing refined carbohydrate. In Pakistan that means white rice, naan, sugary chai and sweets, which is where much of the calorie load sits.
Avoiding alcohol, which compounds liver injury regardless of the metabolic cause.
Coffee has reasonably consistent observational evidence for lower liver fibrosis risk.
Exercise improves liver fat independently of weight loss, which is worth knowing for anyone whose weight is stubborn.
The other treatment
Resmetirom is an alternative approved treatment for MASH with fibrosis, working through a different mechanism on thyroid hormone receptors in the liver.
Neither semaglutide nor resmetirom is registered in Pakistan.
When to get checked
Consider asking about liver assessment if you have:
- Type 2 diabetes or prediabetes
- Central obesity, meaning weight around the abdomen
- Raised triglycerides or low HDL cholesterol
- High blood pressure
- PCOS
- A previous incidental finding of fatty liver on ultrasound
- Persistently raised liver enzymes
Assessment usually starts with liver function tests and an ultrasound. Fibrosis scoring, whether by calculation from blood results or by specialised scanning, indicates whether scarring is present.
If you have been told you have fatty liver and nothing further was said, that is worth following up rather than filing away. Speak with a specialist about fibrosis assessment.
The practical position in Pakistan
Fatty liver is common, underdiagnosed, and now has approved drug treatments that are not available here.
That leaves weight reduction and dietary change as the accessible route, and the thresholds above are the useful targets. WHO's obesity fact sheet sets out the wider risk picture.
GLP-1 appetite support you hold under the tongue works on appetite as a physician-reviewed sublingual supplement with physician review before dispatch. METASLIM™ is not semaglutide, does not carry a liver indication, and ESSENCE describes semaglutide rather than this product. Nobody should present it as a MASH treatment.
What transfers is the mechanism. Liver fat responds to weight reduction and reduced refined carbohydrate intake regardless of how those are achieved, and 5 to 10 percent is where meaningful change begins.
Anyone with diagnosed fatty liver should be managing it with a doctor rather than through a weight loss product alone.
Our guide to GLP-1 benefits beyond weight loss covers the wider evidence, and GLP-1 and heart health covers the overlapping cardiovascular risk.
The summary
MASLD is fat accumulation in the liver. MASH is the inflammatory stage that can progress to fibrosis and cirrhosis.
The ESSENCE phase 3 trial found semaglutide improved liver histology in people with biopsy-proven MASH and fibrosis stage 2 or 3.
The FDA approved semaglutide for MASH with fibrosis in August 2025.
South Asian populations develop fatty liver at lower body weights because of greater visceral fat at any given BMI.
Weight loss of 5 percent improves liver fat, 7 to 10 percent can resolve steatohepatitis, and 10 percent or more is associated with fibrosis improvement.
Fatty liver is usually silent, so people with diabetes, central obesity or raised triglycerides should ask about assessment.
See if you qualify for the program and raise any liver findings at the review.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.